Background {#Sec1}
==========

Optically pure epoxides and vicinal diols, the highly value-added and versatile building blocks, were widely applied in pharmaceutical, fine chemical and agrochemical industries \[[@CR1]--[@CR3]\]. For example, (*R*)-*p*CPED was used for the synthesis of (*R*)-Eliprodil, a neuroprotective agent for the treatment of ischemic stroke, while (*R*)-*m*CPED for β3-adrenergic receptor agonists, such as SR 58611 and AJ-9677 \[[@CR4]\]. With the ever-increasing environmental consciousness, the biocatalysis mediated by whole resting cells or enzymes was considered to be an alternative to chemocatalysis that required expensive chiral ligands and hazardous metals, such as Jacobsen's asymmetric ring-opening hydrolysis and epoxidation \[[@CR5], [@CR6]\].

Epoxide hydrolases (EHs; 3.3.2.-), existing widely in nature, can enantioselectively and/or regioselectively catalyze the oxirane ring-opening hydrolysis of *rac*-epoxides, retaining epoxide enantiomers and/or producing the corresponding chiral diols. Based on the catalytic mechanisms of given EH-substrate pairs, the asymmetric hydrolysis of *rac*-epoxides was divided into two pathways: kinetic resolution and enantioconvergent hydrolysis \[[@CR7]\]. The former can retain single epoxide enantiomers with an intrinsic limitation of 50% maximum yield, while the latter can produce optically pure vicinal diols with 100% theoretically yield \[[@CR8]\].

The mono-enzymatic catalysis was an ideal bioprocess for preparing chiral diols via convergent hydrolysis of epoxides, but few naturally existing EHs had high and opposite regioselectivities towards (*R*)- and (*S*)-epoxides \[[@CR9]\]. To completely and quickly hydrolyze *rac*-epoxide, EH applied in enantioconvergent hydrolysis also have to possess a low enantioselectivity (i.e., enantiomeric ratio, *E*). In view of the merits of mono-enzymatic catalysis and the shortage of highly enantioconvergent EHs, it is necessary to excavate novel EHs or to modify specific local configurations of the existing EHs by protein engineering \[[@CR10]\]. Among the different gene mutagenesis techniques, saturation mutagenesis (SM) at sites lining the enzyme's binding pocket has emerged as a particularly viable approach to improve selectivity \[[@CR11], [@CR12]\]. For example, through five rounds of iterative saturation mutagenesis of nine residues at sites lining in the substrate-binding pocket (SBP) of *Aspergillus niger* M200 EH (*An*EH), its best mutant, named H:12-A1, was selected, whose regioselectivity coefficients (α~*S*~ values) towards (*S*)-SO and -*p*CSO were higher than those of *An*EH, and by which *rac*-SO and -*p*CSO were transformed into (*R*)-PED and -*p*CPED, respectively, with over 70% enantiomeric excess (*ee*~p~) \[[@CR13]\]. Several other research groups also reported the laboratory evolution of residues located in the SBP of EHs \[[@CR14], [@CR15]\].

Previously, to improve the enantioconvergence of *Pv*EH1 towards styrene epoxides, its laboratory evolution was carried out based on the computer-aided design. Among all tested mutants of *Pv*EH1, *Pv*EH1^L105I/M160A/M175I^ (renamed *Pv*EH1^Y3^), was selected (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Its enantioconvergence towards *rac*-*m*CSO increased to 69.7% from 1.0% *ee*~p~ of *Pv*EH1 \[[@CR10]\]. In our present work, the SBP of *Pv*EH1, identified and analyzed using a CAVER 3.0 software (<http://www.caver.cz/>), was divided into three zones. To substantially improve the enantioconvergence of *Pv*EH1, the zones 1 and 3 were subjected, in which all residues were subjected to leucine scanning \[[@CR16]\], namely, substituting target residues with Leu, to identify the sites where Leu mutants had best EH enantioconvergence. Two saturation mutagenesis libraries, *E. coli*/*pveh1*^Y149X^ and /*pveh1*^P184X^, were constructed and screened to select the best substituted residues at their respective sites. Then, the combinatorial mutagenesis of *Pv*EH1^Y3^ was conducted by replacing its Y149 and P184 with the selected best substituted residues, thereby creating one five-site mutant of *Pv*EH1, named *Pv*EH1^Y3/Y149L/P184W^ or *Pv*EH1^Y3Z2^. Lastly, the enantioconvergent hydrolysis of *rac*-*m*CSO was carried out using resting cells of *E. coli*/*pveh1*^Y3Z2^.

Materials and methods {#Sec2}
=====================

Strains, plasmids and chemicals {#Sec3}
-------------------------------

*E. coli* BL21(DE3) and pET-28a(+) (Novagen, Madison, WI) were used for the construction of recombinant plasmid and expression of *pveh1* or its variant, while PrimeSTAR HS DNA polymerase and DpnI endonuclease (TaKaRa, Dalian, China) were used for the leucine scanning and site-saturation mutagenesis of *pveh1* as well as the combinatorial mutagenesis of *pveh1*^Y3^. pET-28a-*pveh1* and -*pveh1*^Y3^ and their corresponding *E. coli/pveh1* and /*pveh1*^Y3^ were constructed and stored in our lab. *Rac*-*m*CSO, (*R*)- and (*S*)-*m*CPED were purchased from Energy (Shanghai, China). All other chemicals were of analytical purity.

Homology modeling of *Pv*EH1 and identification of its SBP {#Sec4}
----------------------------------------------------------

Using the known crystal structure of a *Vigna radiata* EH at 2.0 Å resolution (*Vr*EH1, PDB: 5XMD), sharing 87.4% identity with *Pv*EH1, as the template, the three-dimensional (3-D) structure of *Pv*EH1 was modeled using the MODELLER 9.11 program (<http://salilab.org/modeller/>) (Additional file [1](#MOESM1){ref-type="media"}: Figure S2), and subjected to molecular mechanics optimization by CHARMM27 force field in the GROMACS 4.5 package (<http://www.gromacs.org/>) (Additional file [1](#MOESM1){ref-type="media"}: Figure S3). The 3-D structure with the best geometry quality, which was validated by Structure Assessment in SWISS-MODEL (<https://swissmodel.expasy.org/assess>), was obtained, and visualized by a PyMOL software (<http://pymol.org/>) (Additional file [1](#MOESM1){ref-type="media"}: Figures S4 and S5). The SBP of a modeled *Pv*EH1's 3-D structure was identified and analyzed using a CAVER 3.0 software, and artificially divided into three zones 1--3 (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1The SBP of *Pv*EH1 (**a**) and its three zones (**b**)

Leucine scanning and site-saturation mutagenesis of *Pv*EH1 {#Sec5}
-----------------------------------------------------------

The zones 1 and 3 of *Pv*EH1's SBP were subjected, in which all residues were subjected to leucine scanning. The variants of *pveh1* were designed by substituting the target residues-encoding codons with Leu-encoding codon, synthesized by Genewiz (Suzhou, China), and transformed into *E. coli* BL21, respectively, thereby constructing the corresponding *E. coli* transformants, such as *E. coli*/*pveh1*^Y149L^ and /*pveh1*^P184L^. Through screening, the specific residue sites where Leu mutants catalyzed the enantioconvergent hydrolysis of *rac*-*m*CSO with the highest *ee*~p~ values of (*R*)-*m*CPED were identified for the further studies.

Based on the results of leucine scanning, the saturation mutagenesis of a Y149- or P184-encoding codon in *pveh1* was carried out using a one-step whole-plasmid PCR method \[[@CR17]\]. The primers of saturation mutagenesis were designed as reported previously \[[@CR18]\], and synthesized by Sangon (Shanghai, China) as listed in Additional file [1](#MOESM1){ref-type="media"}: Table S2. Using pET-28a-*pveh1* as a template, the mutagenesis PCR was performed by PrimeSTAR HS DNA polymerase using a pair of primers, Y149X-F/Y149X-R or P184X-F/P184X-R, as following conditions: a denaturation at 95 °C for 4 min, 30 cycles of at 98 °C for 10 s, 55 °C for 15 s and 72 °C for 6 min, and an extra elongation at 72 °C for 10 min. The target PCR products, pET-28a-*pveh1*^Y149X^ or -*pveh1*^P184X^ (X: any one of 20 residues), were digested by DpnI at 37 °C for 6 h to decompose the methylated template DNA, and transformed into *E. coli* BL21(DE3), respectively, thereby constructing the mutagenesis library, *E. coli*/*pveh1*^Y149X^ or /*pveh1*^P184X^. Using both the *ee*~p~ of (*R*)-*m*CPED and *c* of *rac*-*m*CSO as indexes, *E. coli*/*pveh1*^Y149X^ and /*pveh1*^P184X^ were screened, respectively. The best *E. coli* transformant of each library at residue site Y149 or P184 of *Pv*EH1 was selected, expressing the EH mutant with the highest enantioconvergence towards *rac*-*m*CSO.

Combinatorial site-directed mutagenesis of *Pv*EH1^Y3^ {#Sec6}
------------------------------------------------------

The combinatorial site-directed mutagenesis was designed by residue replacements of Y149L and P184W in *Pv*EH1^Y3^, and also carried out by one-step whole-plasmid PCR. The PCR primers were designed according to the nucleotide sequence of *pveh1*^Y3^ and codons encoding the selected mutation residues, and synthesized by Sangon (Additional file [1](#MOESM1){ref-type="media"}: Table S3). Using pET-28a-*pveh1*^Y3^ as the template, the first round of PCR was conducted using a pair of primers, Y149L-F/Y149L-R, under the same PCR conditions as described above. Thereafter, using the first-round PCR product as the template, the second round of PCR was carried out using another pair of primers, P184W-F/P184W-R. The target PCR product, pET-28a-*pveh1*^Y3/Y149L/P184W^ or -*pveh1*^Y3Z2^, was digested by DpnI, and transformed into *E. coli* BL21(DE3), thereby constructing one *E. coli* transformant, named *E. coli*/*pveh1*^Y3Z2^, harboring a five-site variant of *pveh1* or a two-site one of *pveh1*^Y3^.

Analytic methods of HPLC and GC chromatographies {#Sec7}
------------------------------------------------

The activity of *Pv*EH1 or its mutant as well as the conversion ratio (*c*) of *rac*-*m*CSO defined as the ratio of its depleted concentration to initial one was assayed by high-performance liquid chromatography (HPLC), using an e2695 apparatus with an XBridge BEH C18 column (Waters, Milford, MA). The mobile phase of methanol/H~2~O (7:3, v/v) was used at 0.8 mL/min, and continuously monitored using a Waters 2489 UV--Vis detector at 220 nm. The generated diols (*R*)- and (*S*)-*m*CPED were analyzed by HPLC with a Chiralcel OD-H column (Daicel, Osaka, Japan). The *n*-hexane/isopropanol (9:1, v/v) was used as a mobile phase. Because (*R*)- and (*S*)-*m*CSO can not be separated by OD-H, they were assayed by chiral gas chromatography (GC), using a GC-2010 system (Shimadzu, Tokyo, Japan) with a CP-Chirasil-DEX CB column (Agilent, Santa Clara, CA) and a flame ionization detector. The injector and detector temperatures were 220 °C, while the column temperature was programmed from 110 to 190 °C at 10 °C/min. The nitrogen gas carrier was used at 3.0 mL/min.

EH expression of *E. coli* transformant and EH activity assay {#Sec8}
-------------------------------------------------------------

*E. coli* transformant harboring *pveh1* or its variant, such as *E. coli/pveh1* or /*pveh1*^Y3Z2^, was inoculated into LB medium supplemented with 100 μg/mL kanamycin, and cultured at 37 °C overnight as the seed culture. Then, the same fresh medium was inoculated with 2% (v/v) seed culture, and grown until OD~600~ reached 0.6--0.8. The expression of *Pv*EH1 or its mutant was induced by 0.5 mM IPTG at 20 °C for 10 h. The induced transformant cells were collected, and resuspended in 100 mM Na~2~HPO~4~--NaH~2~PO~4~ buffer (pH 7.0) to 100 mg wet cells/mL. *E. coli* BL21(DE3) transformed with pET-28a(+), named *E. coli*/pET-28a, was used as the negative control.

The hydrolytic conditions for the *Pv*EH1 or its mutant activity assay were as follows: 475 μL cell suspension of *E. coli* transformant, suitably diluted with 100 mM phosphate buffer (pH 7.0), was mixed with 25 μL 200 mM *rac*-*m*CSO, incubated at 25 °C for 10 min, and terminated by adding 2 mL methanol. The sample was assayed by HPLC with a C18 column. One EH activity unit (U) was defined as the amount of whole wet cells catalyzing the hydrolysis of 1 μmol *rac*-*m*CSO per minute under the given assay conditions.

EH enantioconvergence assay {#Sec9}
---------------------------

EH enantioconvergence assay was carried out as follows: 1.8 mL suitably diluted cell suspension was mixed with 200 μL 200 mM *rac*-*m*CSO and incubated at 25 °C. Aliquots of 100 μL sample were periodically drawn out, and extracted with 900 μL ethyl acetate for chiral HPLC analysis (or containing 1 mM *n*-hexanol as the internal standard for GC analysis). (*R*)- and (*S*)-*m*CPED were analyzed by chiral HPLC, while (*R*)- and (*S*)-CSO by GC. Both the *ee*~p~ of (*R*)-*m*CPED and *ee*~s~ of (*R*)-CSO were calculated with the equations: *ee*~p~ = \[(*R*~p~ − *S*~p~)/(*R*~p~ + *S*~p~)\] × 100% and *ee*~s~ = \[(*R*~s~ − *S*~s~)/(*R*~s~ + *S*~s~)\] × 100%, in which *R*~p~ and *S*~p~ were the concentrations of (*R*)- and (*S*)-product, while *R*~s~ and *S*~s~ were the concentrations of (*R*)- and (*S*)-substrate. The EH regioselectivity coefficients (β~*R*~ and α~*S*~) were applied to quantitatively evaluate the preference attacking on C~β~ (a less hindered terminal carbon in the oxirane ring) of (*R*)-epoxide and on C~α~ (a more hindered carbon) of (*S*)-epoxide, respectively \[[@CR17]\]. Based on the above parameters, β~*R*~ and α~*S*~ were deduced by linear regression: *ee*~p~ = (α~*S*~ + β~*R*~ − 1) + \[(β~*R*~ − α~*S*~) × *ee*~s~ × (1 − *c*)\]/*c* \[[@CR19]\].

Enantioconvergent hydrolysis of *rac*-*m*CSO by *E. coli/pveh1*^Y3Z2^ {#Sec10}
---------------------------------------------------------------------

As we using the whole cell as the biocatalyst, the regioselective hydrolysis of *rac*-*m*CSO, in a 5 mL 100 mM phosphate buffer (pH 7.0) system containing 20 mM *rac*-*m*CSO and 100 mg wet cells/mL of *E. coli*/*pv*eh1^Y3Z2^, was carried out at 25 °C until the *c* reached over 99%. During the hydrolytic course, aliquots of 100 μL reaction sample were drawn out, extracted with 900 μL ethyl acetate, and analyzed by chiral HPLC to calculate the *c* of *rac*-*m*CSO and *ee*~p~ of (*R*)-*m*CPED.

Results and discussion {#Sec11}
======================

3-D structural analysis of *Pv*EH1 and its SBP identification {#Sec12}
-------------------------------------------------------------

Most EHs belonged to α/β hydrolase superfamily, which consisted of a core domain, an α/β domain and a lid domain (Fig. [2](#Fig2){ref-type="fig"}a) \[[@CR20]\]. Like 3-D structures of other EHs, that of *Pv*EH1 also contained a core domain, a β-sheet packed between two layers of 9 α-helices and a lid domain. Its active center was made up of two polarizing tyrosine residues: Y150 and Y234 and catalytic triad D101-H299-D264 (Fig. [2](#Fig2){ref-type="fig"}b). To avoid mutants losing catalytic activities, these five sites cannot be replaced by other residues. After being homologically modeled and optimized, 3-D structure of *Pv*EH1was analyzed to identify the SBP of *Pv*EH1. The SBP was located in the core domain and the lid domain mainly (Fig. [1](#Fig1){ref-type="fig"}a). It was reported that SBP can be divided according to the zone where the substrate binding with the enzyme \[[@CR16]\]. Herein, as shown in Fig. [1](#Fig1){ref-type="fig"}b, the SBP of *Pv*EH1 was divided into three zones subjectively: zone 1 (residues A120-V126, M129, V135-G142 and Y149), zone 2 (residues D101, Y150, Y234, D264 and H299) and zone 3 (residues M160-T162, A171-M175 and R180-L186). Five residue sites in active center which displayed important roles in the catalytic reaction were in zone 2. Compared with zone 3, zone 1 involved in more residues (17 vs. 15). Similar with the SBP of LEH \[[@CR15]\], that of *Pv*EH1 just looked like a dumbbell, which contained two big cavities and a tunnel connecting them.Fig. 23-D structure of *Pv*EH1 (**a**) and its active center (**b**). The active center of was *Pv*EH1 made up by two polarizing tyrosine residues: Y150 and Y234 and catalytic triad D101-H299-D264

Leucine scanning of the SBP {#Sec13}
---------------------------

Amino acid substitutions at sites lining the SBP of EH may evolve its stereoselectivity \[[@CR20]\]. As lacking the basic understanding of the prerequisites for regioselectivity in nucleophilic attack, each residue in zone 1 and zone 3 was replaced by leucine respectively to construct *E. coli* transformant expressing single-site mutant, except that the residue was leucine originally, for finding out the key sites influencing the enantioconvergence. The *ee*~p~ values and activities of all the mutants towards *rac*-*m*CSO were measured respectively. The results were outlined in Additional file [1](#MOESM1){ref-type="media"}: Table S4. Among all the mutants, *Pv*EH1^Y149L^ displayed a marked increase in enantioconvergence, and *ee*~p~ reached to 55.1%. On other side, residue replacement like M129L in zone 1 reversed the configuration of the main diol product partly (Fig. [3](#Fig3){ref-type="fig"}). The similar phenomenon was also observed in the reshaping of LEH SBP, in that case, a one-site mutant LEH^L114F^ favored the formation of (*R*,*R*)-diol, while LEH the formation of (*S*,*S*)-diol \[[@CR15]\]. Compared with residue replacements in zone 1, those in zone 3 had smaller effects on the catalytic activities (Fig. [3](#Fig3){ref-type="fig"}). For example, different from mutant *Pv*EH1^Y149L^, *Pv*EH1^P184L^ had an increased enantioconvergence and its activity was not decreased. By the way, mutant *Pv*EH1^M129L^ displayed the highest catalytic activity, while mutant *Pv*EH1^Y149L^ the lowest except *Pv*EH1^P137L^ (no activity). There was an increase in the enantioconvergence of mutant *Pv*EH1^Y149L^, but under the comparison with other studies which have been reported, it is still not ideal enough \[[@CR21], [@CR22]\].Fig. 3The enantioconvergence and relative activity part mutants from leucine scanning of zone 1 (contain *Pv*EH1^Y149L^, *Pv*EH1^M129L^ and *Pv*EH1^V126L^) and zone 3 (contain *Pv*EH1^P184L^, *Pv*EH1^T162L^ and *Pv*EH1^M160L^), where catalytic activity of *Pv*EH1 was used as a control

Saturation mutagenesis of Y149 or P184 in *Pv*EH1 {#Sec14}
-------------------------------------------------

To figure out which residues at sites 149 and 184 are most beneficial for improving the enantioconvergence of *Pv*EH1, saturation mutagenesis libraries *E. coli*/*pveh1*^Y149X^ and *E. coli*/*pveh1*^P184X^ were constructed and screened. According to the "22c-trick" method reported by Kille et al. \[[@CR18]\] a special mixture of three primers was employed to create a degeneracy of 22 unique codons coding for the 20 amino acids. To ensure a full coverage of potential mutants, well above a theoretical coverage of \> 95%, all libraries were oversampled at least threefold. That is, 66 *E. coli* transformants from each library were needed. All transformants were screened by HPLC to select the highest mutant in *ee*~p~ value, then confirmed by DNA sequencing.

As a result, in saturation mutagenesis library *E. coli*/*pveh1*^P184X^, four *E. coli* transformants with an over 35% in *ee*~p~ value were obtained, that is, *E. coli*/*pveh1*^P184E^, *E. coli*/*pveh1*^P184D^, *E. coli*/*pveh1*^P184M^ and *E. coli*/*pveh1*^P184W^, whose P184-encoding codon (CCT) was verified to be mutated to E-, D-, M- and W-encoding codons (GAG, GAT, ATG and TGG). As shown in Fig. [4](#Fig4){ref-type="fig"}, *E. coli*/*pveh1*^P184E^ and *E. coli*/*pveh1*^P184D^ could not transform 10 mM *rac*-*m*CSO completely, while *E. coli*/*pveh1*^P184M^ and *E. coli*/*pveh1*^P184W^ could. *E. coli*/*pveh1*^P184W^ displayed the highest enantioconvergence in saturation mutagenesis library *E. coli*/*pveh1*^P184X^. The *ee*~p~ of (*R*)-*m*CPED catalyzed by *E. coli*/*pveh1*^P184W^ was 59.8%, which was nearly 58-fold higher than that by *Pv*EH1. Unfortunately, most *E. coli* transformants in saturation mutagenesis library *E. coli*/*pveh1*^Y149X^ displayed no catalytic activity towards *m*CSO except *E. coli*/*pveh1*^Y149L^. Taking into consideration of studies on active areas in *Vr*EH2 and *St*EH1 \[[@CR21], [@CR23]\], it is likely that amino acid sites around site 149 (including 149) may display important roles in the catalytic activity. On the other hand, the exchanges (Y149L and P184W) were crucial for the regioselectivity regulation \[[@CR13]\].Fig. 4The screening of *Pv*EH1^P184X^ in for the *c* of *rac*-*m*CSO and *ee*~p~ of (*R*)-*m*CPED. After DNA sequencing, four best mutants (*Pv*EH1^P184M^, *Pv*EH1^P184E^, *Pv*EH1^P184D^ and *Pv*EH1^P184W^) were confirmed. The *ee*~p~ and *c* by these four were measured

The regioselectivity coefficients (β~*R*~ and α~*S*~) were applied to quantitatively evaluate the preference attacking on C~β~ of (*R*)-epoxide which could afford the diol of unchanged (*R*)-configuration, and on C~α~ of (*S*)-epoxide which could lead to the (*R*)-diol by inversion of configuration. It was necessary to determine regioselectivity coefficients which were helpful to understand the mechanism of enantioconvergence \[[@CR8]\]. The α~*S*~ values of mutants *Pv*EH1^Y149L^ and *Pv*EH1^P184W^ increased from 10.3% to 65.8% and 66.6%, which straight contributed to the high enantioconvergence. But they were still lower than that of *Pv*EH1^Y3^ (Table [1](#Tab1){ref-type="table"}).Table 1Results of measurements of regioselectivity coefficientsEHβ~*R*~/%α~*S*~/%*ee*~p~/%*Pv*EH194.110.31.0 ± 0.1*Pv*EH1^Y149L^89.265.855.1 ± 1.7*Pv*EH1^P184W^93.266.659.8 ± 1.7*Pv*EH1^Y3^94.475.369.7 ± 3.3*Pv*EH1^Y3Z2^97.997.596.1 ± 2.9

Residue replacements of both Y149L and P184 W in *Pv*EH1^Y3^ {#Sec15}
------------------------------------------------------------

According to the research of Ye et al. \[[@CR10]\] mutant *Pv*EH1^Y3^ displayed a limited enantioconvergence towards *m*CSO (*ee*~p~ = 69.7%). But it still did not meet the requirement of production of (*R*)-*m*CPED. For further enhancing the enantioconvergence, we took the advantage of a cooperative mutational effect from replacements Y149L and P184W \[[@CR24]\]. Mutant *Pv*EH1^Y3Z2^ (containing residues replacements: L105I, M160A, M175I, Y149L and P184W) was engineered, using *Pv*EH1^Y3^ as the template. The enantioconvergence of mutant *Pv*EH1^Y3Z2^ was 94-fold higher than that of *Pv*EH1 (*ee*~p~ 1.0%). Compared regioselectivity coefficients of *Pv*EH1^Y3Z2^ with those of *Pv*EH1, it was observed that almost all the improvement in enantioconvergence was contributed by the increase of α~*S*~ and there was no obviously change in the β~*R*~. The α~*S*~ of *Pv*EH1^Y3Z2^ (97.5%) was higher than that of *St*EH1 (97%) and *mb*EH A (79%) \[[@CR4], [@CR25]\]. Combining with the research by Kotik et al. \[[@CR13]\] we surmised that with the beneficial amino acid exchanging, the position of nucleophilic attack from *Pv*EH1^Y3Z2^ is switched from C~β~ to C~α~ of the oxirane ring of (*S*)-*m*CSO. On the other hand, nucleophilic attack of the oxirane ring of (*R*)-*m*CSO remained largely unaltered in the *Pv*EH1^Y3Z2^, which creates an enantioconvergence towards *rac*-*m*CSO.

Enantioconvergent hydrolysis of *rac*-*m*CSO by *E. coli*/*pveh1*^Y3Z2^ {#Sec16}
-----------------------------------------------------------------------

To confirm the details in the improvement in enantioconvergence of *Pv*EH1^Y3Z2^, the *ee*~p~, *c*, (*R*)- and (*S*)-*m*CPED concentrations in the enantioconvergent hydrolysis of *rac*-*m*CSO catalyzed by *E. coli*/*pveh1*^Y3Z2^ were monitored by chiral HPLC. With 20 mM *rac*-*m*CSO and 100 mg/mL *E. coli*/*pveh1*^Y3Z2^ adding into a volume of 5.0 mL, hydrolysis of *rac*-*m*CSO was carried out by resting cells at 25 °C, until *c* reached over 99%. With a large amount of (*R*)-*m*CPED produced, few (*S*)-*m*CPED was formed, which decreased *ee*~p~ value. Among the hydrolysis, the *ee*~p~ was all over 93%. The *rac*-*m*CSO was transformed into *m*CPED within 6 h completely (*c* = 99.5%). According to the Fig. [5](#Fig5){ref-type="fig"}, at the end of the hydrolysis, the *ee*~p~ and yield were 95.2% and 97.2%, respectively, and the chiral HPLC spectra of production was seen in Additional file [1](#MOESM1){ref-type="media"}: Figure S1b. By now, among all the reported EHs which the author has ever known, *Pv*EH1^Y3Z2^ owned the highest enantioconvergence towards *rac*-*m*CSO, even higher than that of *St*EH1 (*ee*~p~ 91%) and Kau2 (*ee*~p~ 92%) \[[@CR4], [@CR22]\] (Table [2](#Tab2){ref-type="table"}). Compared with enantioconvergences of other EHs towards other substrates, that of *Pv*EH1^Y3Z2^ also displayed an excellent enantioconvergence. On the other hand, compared with the laboratory evolution of *An*EH from *Aspergillus niger* M200 by Kotik et al. \[[@CR13]\] less screening effort was taken and more improvement in enantioconvergence was achieved in this work (*ee*~p~ from 1.0 to 95.2% vs. from 3 to 70.5%).Fig. 5The reaction course of enantioconvergent hydrolysis of *rac*-*m*CSO by whole cells which expressed *Pv*EH1^Y3Z2^. The hydrolysis of *m*CSO was carried out at 25 °C, 2 mL volume containing 20 mM *rac*-*m*CSO, 100 mg/mL *E. coli*/*pv*eh1^Y3Z2^ wet cells until the conversion reached over 99%. The reaction course of aliquots of sample were drawn out periodically, extracted with ethyl acetate, and analyzed by chiral HPLC and GC Table 2Chart of different EHs with high enantioconvergenceEHSubstrate*ee*~p~/%ProductReferences*Pv*EH1^Y3Z2^*m*CSO95.4(*R*)-*m*CPEDThis work*St*EH1*m*CSO91(*R*)-*m*CPED\[[@CR4]\]*Vr*EH2^M263N^*p*NSO98(*R*)-*p*NPED\[[@CR21]\]Kau2*m*CSO92(*R*)-*m*CPED\[[@CR22]\]Kau2 F:13-B11*p*CSO97(*R*)-*p*CPED\[[@CR26]\]*Pv*EH3^G170E/F187I^*p*CSO92.8(*R*)-*p*CPED\[[@CR27]\]

Conclusions {#Sec17}
===========

In this work, the enantioconvergence towards *m*CSO was conferred on *Pv*EH1 by a laboratory evolution. Firstly, after identified and analyzed using a CAVER 3.0 software, the SBP of *Pv*EH1 was studied by leucine scanning. The result shows that *Pv*EH1^Y149L^ and *Pv*EH1^P184L^ have a marked increase in enantioconvergence, which means that sites 149 and 184 played important roles in the enantioconvergent hydrolysis of *rac*-*m*CSO. Secondly, to confirm the best residue at each site, saturation mutagenesis libraries *E. coli*/*pveh1*^Y149X^ and *E. coli*/*pveh1*^P184X^ were constructed and screened. Mutants *Pv*EH1^Y149L^ and *Pv*EH1^P184W^ have the highest enantioconvergence in each saturation mutagenesis library. Thirdly, mutant *Pv*EH1^Y3Z2^ containing five residue replacements was constructed using *Pv*EH1^Y3^ as the template. The enantioconvergence of *Pv*EH1^Y3Z2^ was 94-fold higher than that of *Pv*EH1. The analysis of regioselectivity coefficients indicated that the position of nucleophilic attack from mutant *Pv*EH1^Y3Z2^ switched from C~β~ to C~α~ of the oxirane ring of (*S*)-*m*CSO, which led to the improvement in enantioconvergence. At last, enantioconvergent hydrolysis by *E. coli/pveh1*^Y3Z2^ was monitored. The result showed that the *ee*~p~ and yield of (*R*)-*m*CPED were 95.2% and 97.2%, when the *rac*-*m*CSO was transformed into *m*CPED completely (*c* = 99.5%).

Supplementary information
=========================

 {#Sec18}

**Additional file 1: Figure S1.** Chiral HPLC spectra for enantioconvergence hydrolytic of *rac*-*m*CSO by *Pv*EH1^Y3Z2^ including analysis of *rac*-*m*CSO and *rac*-*m*CPED (a), and analysis of (*R*)-*m*CPED (b). **Figure S2.** The comparison of the homology model (red) with the template model (green). **Figure S3.** The change in RMSD values of the whole model. The RMSD value of the whole model tends to 0.18 nm. **Figure S4.** The Ramachandran plots of the model. The Ramachandran favored residue sites was 96.07%, which means that the most distribution of residues is good and the model could be believed. **Figure S5.** The local quality estimate of every residue. Compared with the template model, the identity of amino acids lining the substrate-binding pocket was 93.94%. The local similarity value of most residue in the substrate-binding pocket was over 0.8, which means the residue was highly similar to the template model. **Table S1.** Enantioconvergences and activities of *Pv*EH1 and its three-site mutant towards *rac*-*m*CSO. **Table S2.** PCR primers used for the site-saturation saturation mutagenesis of *pveh1*. **Table S3.** PCR primers used for combinatorial site-directed mutagenesis of *pveh1*^*Y3*^. **Table S4.** Catalytic characteristics of representative mutants from leucine scanning mutagenesis.
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